{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T22:43:49Z","timestamp":1787352229031,"version":"build-2736575974"},"reference-count":91,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.jconrel.2022.05.004","type":"journal-article","created":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T14:24:14Z","timestamp":1652279054000},"page":"175-182","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"special_numbering":"C","title":["Self-assembled polysaccharide nanogel delivery system for overcoming tumor immune resistance"],"prefix":"10.1016","volume":"347","author":[{"given":"Daisuke","family":"Muraoka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naozumi","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Shiku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunari","family":"Akiyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2022.05.004_bb0005","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","article-title":"Delivery technologies for cancer immunotherapy","volume":"18","author":"Riley","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0010","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s41568-019-0186-9","article-title":"Improving cancer immunotherapy through nanotechnology","volume":"19","author":"Goldberg","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2022.05.004_bb0015","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41578-019-0110-7","article-title":"Material design for lymph node drug delivery","volume":"4","author":"Schudel","year":"2019","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0020","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jconrel.2017.08.009","article-title":"Lymph node targeting strategies to improve vaccination efficacy","volume":"267","author":"Jiang","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.05.004_bb0025","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1038\/s41467-019-11911-5","article-title":"Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers","volume":"10","author":"Zhang","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0030","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41551-018-0236-8","article-title":"TLR7\/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy","volume":"2","author":"Rodell","year":"2018","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0035","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/nrd.2018.102","article-title":"Cancer: re-educating tumour-associated macrophages with nanoparticles","volume":"17","author":"Cully","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0040","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41571-021-00507-y","article-title":"Intratumoural administration and tumour tissue targeting of cancer immunotherapies","volume":"18","author":"Melero","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0045","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0050","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nature."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0055","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","article-title":"Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial","volume":"565","author":"Keskin","year":"2019","journal-title":"Nature."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0060","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0065","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0070","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0075","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0080","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0085","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1056\/NEJMoa1716435","article-title":"Recurrent glioblastoma treated with recombinant poliovirus","volume":"379","author":"Desjardins","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0090","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/cas.13027","article-title":"Oncolytic virus therapy: a new era of cancer treatment at dawn","volume":"107","author":"Fukuhara","year":"2016","journal-title":"Cancer Sci."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0095","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1038\/s41467-021-23244-3","article-title":"PLGA-particle vaccine carrying TLR3\/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy","volume":"12","author":"Koerner","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0100","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1186\/s12951-021-01116-8","article-title":"Intracellular signaling pathway in dendritic cells and antigen transport pathway in vivo mediated by an OVA@DDAB\/PLGA nano-vaccine","volume":"19","author":"Han","year":"2021","journal-title":"J. Nanobiotechnology."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0105","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.biomaterials.2013.10.003","article-title":"Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response","volume":"35","author":"Thomas","year":"2014","journal-title":"Biomaterials."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0110","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.addr.2020.06.003","article-title":"Dawn of lipid nanoparticles in lymph node targeting: potential in cancer immunotherapy","volume":"167","author":"Nakamura","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0115","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1021\/acs.molpharmaceut.1c00263","article-title":"Multifunctional traceable liposomes with temperature-triggered drug release and neovasculature-targeting properties for improved cancer chemotherapy","volume":"18","author":"Yuba","year":"2021","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0120","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.2147\/IJN.S125866","article-title":"Cationic liposomes promote antigen cross-presentation in dendritic cells by alkalizing the lysosomal pH and limiting the degradation of antigens","volume":"12","author":"Gao","year":"2017","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2022.05.004_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2015.05.022","article-title":"Lymphatic-targeted cationic liposomes: a robust vaccine adjuvant for promoting long-term immunological memory","volume":"213","author":"Wang","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.05.004_bb0130","doi-asserted-by":"crossref","first-page":"6231","DOI":"10.1021\/acs.langmuir.8b04304","article-title":"Nanogels and microgels: from model colloids to applications, recent developments, and future trends","volume":"35","author":"Karg","year":"2019","journal-title":"Langmuir."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0135","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/tcr.201000008","article-title":"Nanogel engineering for new nanobiomaterials: from chaperoning engineering to biomedical applications","volume":"10","author":"Sasaki","year":"2010","journal-title":"Chem. Rec."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0140","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jconrel.2015.11.009","article-title":"Nanogels: an overview of properties, biomedical applications and obstacles to clinical translation","volume":"240","author":"Soni","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.05.004_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2021.130446","article-title":"Nanogels: an overview of properties, biomedical applications, future research trends and developments","volume":"1239","author":"Anooj","year":"2021","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0150","doi-asserted-by":"crossref","first-page":"9872","DOI":"10.1021\/jacs.1c03772","article-title":"Squaric ester-based, pH-degradable nanogels: modular nanocarriers for safe, systemic administration of toll-like receptor 7\/8 agonistic immune modulators","volume":"143","author":"Huppertsberg","year":"2021","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0155","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/nbt.4181","article-title":"Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery","volume":"36","author":"Tang","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0160","doi-asserted-by":"crossref","first-page":"8291","DOI":"10.1021\/acsabm.1c00828","article-title":"Reduction-sensitive protein nanogels enhance uptake of model and tumor lysate antigens in vitro by mouse- and human-derived dendritic cells","volume":"4","author":"Berti","year":"2021","journal-title":"ACS Appl. Bio Mater."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0165","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1021\/acs.bioconjchem.8b00319","article-title":"Targeting protumoral tumor-associated macrophages with nanobody-functionalized nanogels through strain promoted azide alkyne cycloaddition ligation","volume":"29","author":"Nuhn","year":"2018","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0170","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202006116","article-title":"A virus-mimicking nucleic acid nanogel reprograms microglia and macrophages for glioblastoma therapy","volume":"33","author":"Gao","year":"2021","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0175","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1021\/ma00064a011","article-title":"Self-aggregates of hydrophobized polysaccharides in water - formation and characteristics of nanoparticles","volume":"26","author":"Akiyoshi","year":"1993","journal-title":"Macromolecules."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0180","doi-asserted-by":"crossref","first-page":"6110","DOI":"10.1021\/ja953843c","article-title":"Macromolecular complexation between bovine serum albumin and the self-assembled hydrogel nanoparticle of hydrophobized polysaccharides","volume":"118","author":"Nishikawa","year":"1996","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0185","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1021\/bc9801272","article-title":"Molecular chaperone-like activity of hydrogel nanoparticles of hydrophobized pullulan: thermal stabilization with refolding of carbonic anhydrase B","volume":"10","author":"Akiyoshi","year":"1999","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0190","doi-asserted-by":"crossref","first-page":"5583","DOI":"10.1016\/j.biomaterials.2009.06.010","article-title":"The binding of pullulan modified cholesteryl nanogels to Abeta oligomers and their suppression of cytotoxicity","volume":"30","author":"Boridy","year":"2009","journal-title":"Biomaterials."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0195","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0168-3659(98)00017-0","article-title":"Self-assembled hydrogel nanoparticle of cholesterol-bearing pullulan as a carrier of protein drugs: complexation and stabilization of insulin","volume":"54","author":"Akiyoshi","year":"1998","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.05.004_bb0200","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/nmat2784","article-title":"Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines","volume":"9","author":"Nochi","year":"2010","journal-title":"Nat. Mater."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0205","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jconrel.2009.06.025","article-title":"Raspberry-like assembly of cross-linked nanogels for protein delivery","volume":"140","author":"Hasegawa","year":"2009","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.05.004_bb0210","doi-asserted-by":"crossref","first-page":"5080","DOI":"10.1002\/adma.201501557","article-title":"Nanocarrier-integrated microspheres: Nanogel tectonic engineering for advanced drug-delivery systems","volume":"27","author":"Tahara","year":"2015","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0215","article-title":"Nanogel tectonics for tissue engineering: protein delivery systems with nanogel chaperones","volume":"7","author":"Hashimoto","year":"2018","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0220","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.addr.2015.10.004","article-title":"Current advances in self-assembled nanogel delivery systems for immunotherapy","volume":"95","author":"Tahara","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0225","first-page":"3385","article-title":"A novel hydrophobized polysaccharide\/oncoprotein complex vaccine induces in vitro and in vivo cellular and humoral immune responses against HER2-expressing murine sarcomas","volume":"58","author":"Gu","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0230","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1182\/blood.V99.10.3717","article-title":"Presentation of a major histocompatibility complex class 1-binding peptide by monocyte-derived dendritic cells incorporating hydrophobized polysaccharide-truncated HER2 protein complex: implications for a polyvalent immuno-cell therapy","volume":"99","author":"Ikuta","year":"2002","journal-title":"Blood."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0235","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1349-7006.2007.00705.x","article-title":"Humoral immune responses in patients vaccinated with 1\u2013146 HER2 protein complexed with cholesteryl pullulan nanogel","volume":"99","author":"Kageyama","year":"2008","journal-title":"Cancer Sci."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0240","doi-asserted-by":"crossref","first-page":"7397","DOI":"10.1158\/1078-0432.CCR-06-1546","article-title":"HER2-specific T-cell immune responses in patients vaccinated with truncated HER2 protein complexed with nanogels of cholesteryl pullulan","volume":"12","author":"Kitano","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0245","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/mi.2015.5","article-title":"Nanogel-based pneumococcal surface protein a nasal vaccine induces microRNA-associated Th17 cell responses with neutralizing antibodies against Streptococcus pneumoniae in macaques","volume":"8","author":"Fukuyama","year":"2015","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0250","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1021\/acs.molpharmaceut.0c01003","article-title":"Characterization and specification of a trivalent protein-based pneumococcal vaccine formulation using an adjuvant-free nanogel nasal delivery system","volume":"18","author":"Yuki","year":"2021","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0255","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1016\/j.vaccine.2021.04.069","article-title":"A nanogel-based trivalent PspA nasal vaccine protects macaques from intratracheal challenge with pneumococci","volume":"39","author":"Nakahashi-Ouchida","year":"2021","journal-title":"Vaccine."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0260","doi-asserted-by":"crossref","first-page":"30983","DOI":"10.1021\/acsami.8b09348","article-title":"Nanovaccine incorporated with hydroxychloroquine enhances antigen cross-presentation and promotes antitumor immune responses","volume":"10","author":"Liu","year":"2018","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2022.05.004_bb0265","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/j.celrep.2017.02.026","article-title":"Macrophage death following influenza vaccination initiates the inflammatory response that promotes dendritic cell function in the draining lymph node","volume":"18","author":"Chatziandreou","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0270","doi-asserted-by":"crossref","first-page":"9209","DOI":"10.1021\/nn502975r","article-title":"Nanogel-based immunologically stealth vaccine targets macrophages in the medulla of lymph node and induces potent antitumor immunity","volume":"8","author":"Muraoka","year":"2014","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2022.05.004_bb0275","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1080\/21645515.2015.1117714","article-title":"PLGA particulate delivery systems for subunit vaccines: linking particle properties to immunogenicity","volume":"12","author":"Silva","year":"2016","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0280","doi-asserted-by":"crossref","first-page":"44644","DOI":"10.18632\/oncotarget.10183","article-title":"Maturation of dendritic cells by pullulan promotes anti-cancer effect","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0285","doi-asserted-by":"crossref","first-page":"6497","DOI":"10.1158\/1078-0432.CCR-12-2189","article-title":"Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients","volume":"18","author":"Sabbatini","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0290","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1073\/pnas.1319268111","article-title":"Nonagonistic Dectin-1 ligand transforms CpG into a multitask nanoparticulate TLR9 agonist","volume":"111","author":"Kobiyama","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0295","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/eji.200737984","article-title":"Nanoparticles target distinct dendritic cell populations according to their size","volume":"38","author":"Manolova","year":"2008","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0300","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1172\/JCI81083","article-title":"Beyond antigens and adjuvants: formulating future vaccines","volume":"126","author":"Moyer","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0305","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1084\/jem.20100643","article-title":"Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity","volume":"207","author":"Sakuishi","year":"2010","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0310","doi-asserted-by":"crossref","first-page":"6682","DOI":"10.1073\/pnas.1420370112","article-title":"Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses","volume":"112","author":"Liu","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0315","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0320","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.it.2015.02.008","article-title":"Overcoming T cell exhaustion in infection and cancer","volume":"36","author":"Pauken","year":"2015","journal-title":"Trends Immunol."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0325","first-page":"95","article-title":"Vaccines combined with immune checkpoint antibodies promote cytotoxic T-cell activity and tumor eradication, Cancer","volume":"4","author":"Ali","year":"2016","journal-title":"Immunol. Res."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0330","first-page":"201","article-title":"Subclinical renal tubular dysfunction in systemic lupus erythematosus","volume":"91","author":"Aguirre","year":"1988","journal-title":"Med. Clin. (Barc.)"},{"key":"10.1016\/j.jconrel.2022.05.004_bb0335","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41541-022-00433-9","article-title":"Neoantigen cancer vaccine augments anti-CTLA-4 efficacy","volume":"7","author":"Salvatori","year":"2022","journal-title":"npj Vaccines."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0340","doi-asserted-by":"crossref","first-page":"8074","DOI":"10.1039\/C9RA10066K","article-title":"Synergistic anti-tumor efficacy by combination therapy of a self-assembled nanogel vaccine with an immune checkpoint anti-PD-1 antibody","volume":"10","author":"Miura","year":"2020","journal-title":"RSC Adv."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0345","doi-asserted-by":"crossref","first-page":"e731","DOI":"10.1016\/S1470-2045(17)30607-1","article-title":"De-novo and acquired resistance to immune checkpoint targeting","volume":"18","author":"Syn","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0350","article-title":"Targeting monocytes\/macrophages in fibrosis and cancer diseases: therapeutic approaches","author":"Conte","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0355","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1172\/JCI97642","article-title":"Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance","volume":"129","author":"Muraoka","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0360","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3389\/fimmu.2014.00614","article-title":"Molecular mechanisms that influence the macrophage m1-m2 polarization balance","volume":"5","author":"Wang","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0365","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0370","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.3389\/fonc.2019.01512","article-title":"Evaluating the polarization of tumor-associated macrophages into M1 and M2 phenotypes in human cancer tissue: technicalities and challenges in routine clinical practice","volume":"9","author":"Jayasingam","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0375","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1158\/1535-7163.MCT-07-0579","article-title":"Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma","volume":"7","author":"Miselis","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0380","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3389\/fimmu.2014.00587","article-title":"Depletion of tumor-associated macrophages slows the growth of chemically induced mouse lung adenocarcinomas","volume":"5","author":"Fritz","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0385","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/sj.bjc.6603240","article-title":"Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach","volume":"95","author":"Zeisberger","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2022.05.004_bb0390","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jconrel.2014.07.040","article-title":"Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8(+) T cell response: a comparative study","volume":"192","author":"Cruz","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.05.004_bb0395","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/mt.2015.175","article-title":"Delivery of siRNAs to dendritic cells using DEC205-targeted lipid nanoparticles to inhibit immune responses","volume":"24","author":"Katakowski","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0400","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1038\/jid.2015.152","article-title":"In situ delivery of antigen to DC-SIGN(+)CD14(+) dermal dendritic cells results in enhanced CD8(+) T-cell responses","volume":"135","author":"Fehres","year":"2015","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0405","doi-asserted-by":"crossref","first-page":"990","DOI":"10.3389\/fimmu.2020.00990","article-title":"Lipo, Lipo-based vaccines as an approach to target dendritic cells for induction of T- and iNKT cell responses","volume":"11","author":"Stolk","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0410","doi-asserted-by":"crossref","first-page":"4322","DOI":"10.4049\/jimmunol.1400491","article-title":"Different antigen-processing activities in dendritic cells, macrophages, and monocytes lead to uneven production of HIV epitopes and affect CTL recognition","volume":"193","author":"Dinter","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0415","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1136\/jcp.54.9.669","article-title":"Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer","volume":"54","author":"J\u00e4ger","year":"2001","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0420","first-page":"11","article-title":"Getting personal with neoantigen-based therapeutic cancer vaccines, Cancer","volume":"1","author":"Hacohen","year":"2013","journal-title":"Immunol. Res."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0425","doi-asserted-by":"crossref","first-page":"6160","DOI":"10.4049\/jimmunol.0802664","article-title":"Tumor regulatory T cells potently abrogate antitumor immunity","volume":"182","author":"Liu","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0430","doi-asserted-by":"crossref","first-page":"E6546","DOI":"10.1073\/pnas.1720113115","article-title":"Fatty acid metabolism complements glycolysis in the selective regulatory T cell expansion during tumor growth","volume":"115","author":"Pacella","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0435","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","article-title":"The nature of myeloid-derived suppressor cells in the tumor microenvironment","volume":"37","author":"Kumar","year":"2016","journal-title":"Trends Immunol."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0440","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.semcancer.2005.07.006","article-title":"Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators","volume":"16","author":"Ben-Baruch","year":"2006","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0445","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40169-019-0226-9","article-title":"Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma","volume":"8","author":"Daniel","year":"2019","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0450","doi-asserted-by":"crossref","first-page":"400","DOI":"10.4049\/jimmunol.1701041","article-title":"Metabolic barriers to T cell function in tumors","volume":"200","author":"Sugiura","year":"2018","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2022.05.004_bb0455","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1046\/j.0022-202x.2001.01665.x","article-title":"Expression and function of the mannose receptor CD206 on epidermal dendritic cells in inflammatory skin diseases","volume":"118","author":"Wollenberg","year":"2002","journal-title":"J. Invest. Dermatol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365922002577?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365922002577?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:18:41Z","timestamp":1759162721000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365922002577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":91,"alternative-id":["S0168365922002577"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2022.05.004","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Self-assembled polysaccharide nanogel delivery system for overcoming tumor immune resistance","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2022.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}